Taurine From Bone Marrow Fuels Aggressive Leukemia Growth

This groundbreaking Nature study reveals how the bone marrow microenvironment actively supports leukemia through taurine production, fundamentally changing our understanding of cancer-niche interactions. Researchers used temporal single-cell RNA sequencing to map how bone marrow stromal cells change during leukemia progression, discovering that osteolineage cells increasingly produce taurine via the enzyme CDO1.

The team analyzed 15,695 non-hematopoietic bone marrow cells across disease stages, identifying 21 distinct stromal cell clusters that undergo significant remodeling. They found that mesenchymal stromal cells and osteolineage populations expand during disease progression, while their normal functions like bone mineralization become impaired. Crucially, taurine biosynthesis becomes restricted to these osteolineage cells and increases as disease advances.

Using CRISPR screens and patient samples, researchers demonstrated that the taurine transporter TAUT (SLC6A6) is essential for aggressive myeloid leukemias. Genetic deletion of TAUT in mouse models significantly impaired leukemia growth and improved survival outcomes. In human acute myeloid leukemia cells, TAUT inhibition synergized with venetoclax, a standard therapy, to block cancer cell growth - particularly relevant since TAUT expression is elevated in venetoclax-resistant cases.

Mechanistically, the study revealed that taurine uptake activates mTOR signaling and downstream glycolysis through RAG-GTP regulation. This metabolic reprogramming appears critical for leukemia stem cell function. The findings establish taurine as an unexpected cancer-promoting signal, contrasting with its known neuroprotective and anti-inflammatory roles in healthy tissues.

This work provides the first comprehensive temporal map of stromal signals during leukemia progression and identifies a novel therapeutic vulnerability that could be targeted alongside existing treatments.